Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by accumulation of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD). Many people have collection of fat in the liver, and for most people it causes no symptoms and no problems. But in some cases, the fat causes inflammation and damages cells in the liver. NASH can get poorer and cause damage to the liver, which leads to cirrhosis. NASH is seen more often in women than in men.

Download exclusive Brochure of this report: http://tinyurl.com/zfuey76

The cause of NASH is yet unclear, though research is ongoing in an attempt to find effective treatments. At present, treatment of NASH focuses on regulating some of the medical conditions associated with it such as diabetes and obesity and monitoring for advancement. As with nonalcoholic fatty liver disease, people with NASH should be vaccinated against hepatitis A and B if they are not already immune. Diagnosis of NASH is often done with routine laboratory tests. Further tests help confirm the presence of NASH and exclude other types of liver disease. Imaging tests such as ultrasound, CT scan, or magnetic resonance imaging [MRI] may expose fat accumulation in the liver but cannot differentiate NASH from other causes of liver disease that have a similar appearance.

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth in revenue is majorly due to Elafibranor which is considered to be the most advanced drug in this category.

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.),